Recludix Pharma, a 2024 Fierce 15 biotech company and a renowned leader in the discovery of inhibitors for challenging protein targets, has made a groundbreaking announcement. The company has nominated REX-8756, a first-in-class oral STAT6 inhibitor, as a lead development candidate in the fight against inflammatory diseases such as asthma, atopic dermatitis, and rheumatoid arthritis. […]
Category: Recludix Pharma
Advancements in Recludix Pharma’s STAT6 Inhibitors
In the often complex and intricate world of biotechnology, the role of STAT6 inhibitors is emerging as a pivotal one, offering a beacon of hope for the future of immune response and inflammation regulation. Recludix Pharma, a trailblazer in this sphere, is diligently working on pioneering innovative solutions that are poised to redefine the treatment […]